A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine
in a Randomized Controlled Trial and Observational Studies

Mahanjit      Konwar; Miteshkumar      Maurya; Urmila   M.   Thatte; Nithya   J.   Gogtay; Debdipta      Bose
Abstract

Introduction: Hydroxychloroquine (HCQ) has recently become the focus of attention in the current COVID-19 pandemic. With an increase in the off-label use of HCQ, concern for the safety of HCQ has been raised. We, therefore, performed this systematic review to analyze the safety data of HCQ against placebo and active treatment in various disease conditions.
Methods: We searched PubMed, Embase, and Cochrane for Randomized Controlled Trials (RCTs) and Observational Studies (OSs) that evaluated HCQ for the treatment of any disease other than COVID19 in adult patients up to May 2020. We assessed the quality of the included studies using Risk of Bias 2 (for RCTs) and Newcastle–Ottawa Scale (for OSs). Data were analyzed with randomeffect meta-analysis. Sensitivity and subgroup analyses were performed to identify heterogeneity.
Results: A total of 6641 studies were screened, and 49 studies (40 RCTs and 9 OSs) with a total sample size of 35044 patients were included. The use of HCQ was associated with higher risks of TDAEs as compared to placebo/no active treatment [RR 1.47, 95%CI 1.03-2.08]. When HCQ was compared with active treatments, the risks of AEs [RR 0.74, 95% CI 0.63-0.86] and TDAEs were less in the HCQ arm [RR 0.57, 95% CI 0.39-0.81]. The outcomes did not differ in the sensitivity analysis.
Conclusion: The results suggest that the use of HCQ was associated with a lower risk of AEs and TDAEs as compared to active treatment, whereas posing higher risk of TDAEs as compared to placebo.
Keywords: Adverse events, active treatments, placebo, randomised controlled trial, HCQ, rheumatoid arthritis.
[1] 
Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol  2012; 42(2): 145-53.
[http://dx.doi.org/10.1007/s12016-010-8243-x] [PMID:  21221847] 
[2] 
 Hydroxychloroquine - drug bank. Drugbankca 2020. Available
from: https://www.drugbank.ca/drugs/DB01611#reference-L8072
[3] 
 Model list of essential medicines. Appswhoint 2019. Available
from: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf
[4] 
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis  2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID:  14592603] 
[5] 
Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis  2020; 20(10): 1118-9.
[http://dx.doi.org/10.1016/S1473-3099(20)30313-3] [PMID:  32311324] 
[6] 
 Hydroxychloroquine sulfate tablets, USP. Accessdata Fda Gov
2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf
[7] 
Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y-M. Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf  2018; 41(10): 919-31.
[http://dx.doi.org/10.1007/s40264-018-0689-4] [PMID:  29858838] 
[8] 
Updates L.  Live updates: Fills and prices for unproven covid-19
treatments - GoodRx. The GoodRx Prescription Savings Blog
2020. Available from: https://www.goodrx.com/blog/covid-19-treatments-fill-increases-price-changes/
[9] 
Ledsom A.  ydroxychloroquine–number of prescriptions explodes
in france. Forbes Available from: https://www.forbes.com/sites/alexledsom/2020/05/10/hydroxychloroquinenumber-of-prescriptions-explode-in-france/
[10] 
 Research C for DE and. FDA cautions against use of hydroxychloroquine
or chloroquine for COVID-19 outside of the hospital setting
or a clinical trial due to risk of heart rhythm problems. FDA
2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
[11] 
 Hydroxychloroquine sulphate tablests, USP. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
[12] 
Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ  2020; 369: m1849.
[http://dx.doi.org/10.1136/bmj.m1849] [PMID:  32409561] 
[13] 
 The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate healthcare interventions:
Explanation and elaboration. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714672/
[14] 
 Common Terminology Criteria for Adverse Events (CTCAE) version
5.0 [last updated in 2017]. [pdf] Bethesda, Maryland, USA:
National Cancer Institute, NIH, pp.1-146. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
[15] 
Tietje C, Brouder A.  2009. Handbook of Transnational
Economic Governance Regimes (Transnational Economic Governance
Regimes). Sussex: Martinus Nijhoff Publishers, pp.1041-
1053.
[16] 
Abraham J.  RoB 2: A revised cochrane risk-of-bias tool for randomized
trial. 2010. Available from: /bias/resources/rob-2-revisedcochrane-
risk-bias-tool-randomized-trials
[17] 
Wells GA, Shea B, O’Connell D, et al.  Ottawa Hospital Research
Institute. Available from: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp
[18] 
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials  1986; 7(3): 177-88.
[http://dx.doi.org/10.1016/0197-2456(86)90046-2] [PMID:  3802833] 
[19] 
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ  2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID:  12958120] 
[20] 
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ  1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID:  9310563] 
[21] 
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics  1994; 50(4): 1088-101.
[http://dx.doi.org/10.2307/2533446] [PMID:  7786990] 
[22] 
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics  2000; 56(2): 455-63.
[http://dx.doi.org/10.1111/j.0006-341X.2000.00455.x] [PMID:  10877304] 
[23] 
Boonpiyathad T, Sangasapaviliya A. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. Eur Ann Allergy Clin Immunol  2017; 49(5): 220-4.
[http://dx.doi.org/10.23822/EurAnnACI.1764-1489.11] [PMID:  28884989] 
[24] 
Borg AA, Davis MJ, Fowler PD, Shadforth MF, Dawes PT. Rifampicin in early rheumatoid arthritis. Scand J Rheumatol  1993; 22(1): 39-42.
[http://dx.doi.org/10.3109/03009749309095110] [PMID:  8434246] 
[25] 
Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med  1993; 119(11): 1067-71.
[http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00002] [PMID:  8239224] 
[26] 
Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: A randomized, double-blind, placebo controlled clinical trial-an Indian experience. Curr Med Res Opin  2007; 23(9): 2227-34.
[http://dx.doi.org/10.1185/030079907X219634] [PMID:  17692155] 
[27] 
Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol  1991; 30(6): 451-4.
[http://dx.doi.org/10.1093/rheumatology/30.6.451] [PMID:  1747702] 
[28] 
Desta M, Tadesse A, Gebre N, Barci BM, Torrey EF, Knable MB. Controlled trial of hydroxychloroquine in schizophrenia. J Clin Psychopharmacol  2002; 22(5): 507-10.
[http://dx.doi.org/10.1097/00004714-200210000-00011] [PMID:  12352275] 
[29] 
Erkan D, Unlu O, Sciascia S, et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus  2018; 27(3): 399-406.
[http://dx.doi.org/10.1177/0961203317724219] [PMID:  28764618] 
[30] 
Faarvang KL, Egsmose C, Kryger P, Pødenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomised double blind trial. Ann Rheum Dis  1993; 52(10): 711-5.
[http://dx.doi.org/10.1136/ard.52.10.711] [PMID:  7903034] 
[31] 
Fong T, Trinkaus K, Adkins D, et al. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant  2007; 13(10): 1201-6.
[http://dx.doi.org/10.1016/j.bbmt.2007.06.012] [PMID:  17889357] 
[32] 
Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial. Diabetes Res Clin Pract  2002; 55(3): 209-19.
[http://dx.doi.org/10.1016/S0168-8227(01)00325-4] [PMID:  11850097] 
[33] 
Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA  2014; 312(3): 249-58.
[http://dx.doi.org/10.1001/jama.2014.7682] [PMID:  25027140] 
[34] 
Haar D, Sølvkjaer M, Unger B, Rasmussen K-JE, Christensen L, Hansen TM. A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol  1993; 22(3): 113-8.
[http://dx.doi.org/10.3109/03009749309099254] [PMID:  8316771] 
[35] 
A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med  1995; 98(2): 156-68.
[http://dx.doi.org/10.1016/S0002-9343(99)80399-4] [PMID:  7847432] 
[36] 
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J.  A randomised phase II trial of hydroxychloroquine and
imatinib versus imatinib alone for patients with chronic myeloid
leukaemia in major cytogenetic response with residual disease. Leukemia 2020. Available from:http://www.nature.com/articles/s41375-019-0700-9
[37] 
Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes  2020; 12(1): 91-4.
[http://dx.doi.org/10.1111/1753-0407.12989] [PMID:  31574564] 
[38] 
Jessop JD, O’Sullivan MM, Lewis PA, et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol  1998; 37(9): 992-1002.
[http://dx.doi.org/10.1093/rheumatology/37.9.992] [PMID:  9783766] 
[39] 
Jokar M, Keyvanpajouh K. The effect of hydroxychloroquine on symptoms of knee osteoarthritis: A double-blind randomized controlled clinical trial. Iran J Med Sci  2013; 38(3): 6.
[40] 
Karasic TB, O’Hara MH, Loaiza-Bonilla A, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: A phase 2 randomized clinical trial. JAMA Oncol  2019; 5(7): 993-8.
[http://dx.doi.org/10.1001/jamaoncol.2019.0684] [PMID:  31120501] 
[41] 
Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: A randomized trial. Ann Intern Med  2018; 168(6): 385-95.
[http://dx.doi.org/10.7326/M17-1430] [PMID:  29459986] 
[42] 
Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev  2020; 19(4)102491
[http://dx.doi.org/10.1016/j.autrev.2020.102491] [PMID:  32084592] 
[43] 
Lajoie J, Birse K, Mwangi L, et al. Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. J Int AIDS Soc  2018; 21(7)e25150
[http://dx.doi.org/10.1002/jia2.25150] [PMID:  30047573] 
[44] 
Lee W, Ruijgrok L, Boxma-de Klerk B, et al. Efficacy of hydroxychloroquine in hand osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken)  2018; 70(9): 1320-5.
[http://dx.doi.org/10.1002/acr.23471] [PMID:  29125901] 
[45] 
Liu L-J, Yang YZ, Shi S-F, et al. Effects of hydroxychloroquine on proteinuria in Iga nephropathy: A randomized controlled trial. Am J Kidney Dis  2019; 74(1): 15-22.
[http://dx.doi.org/10.1053/j.ajkd.2019.01.026] [PMID:  30922594] 
[46] 
Le Loët X, Nordström D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: Evidence from the OMEGA trial. J Rheumatol  2008; 35(8): 1538-44.
[47] 
Majzoobi MM, Hashemi SH, Mamani M, Keramat F, Poorolajal J, Ghasemi BHR. Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: A single-blind, randomized clinical trial. Int J Antimicrob Agents  2018; 51(3): 365-9.
[http://dx.doi.org/10.1016/j.ijantimicag.2017.08.009] [PMID:  28826825] 
[48] 
O’Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum  2002; 46(5): 1164-70.
[http://dx.doi.org/10.1002/art.10228] [PMID:  12115219] 
[49] 
O’Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum  2001; 44(10): 2235-41.
[http://dx.doi.org/10.1002/1529-0131(200110)44:10<2235:AID-ART385>3.0.CO;2-A] [PMID:  11665963] 
[50] 
Pareek A, Khopkar U, Sacchidanand S, Chandurkar N, Naik GS. Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study. Indian J Dermatol Venereol Leprol  2008; 74(1): 18-22.
[http://dx.doi.org/10.4103/0378-6323.38401] [PMID:  18187817] 
[51] 
Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: A double blind, randomized comparison with pioglitazone. Curr Med Res Opin  2014; 30(7): 1257-66.
[http://dx.doi.org/10.1185/03007995.2014.909393] [PMID:  24669876] 
[52] 
Pareek A, Chandurkar N, Thulaseedharan NK, et al. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: A randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med Res Opin  2015; 31(11): 2105-17.
[http://dx.doi.org/10.1185/03007995.2015.1087989] [PMID:  26371518] 
[53] 
Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA  2012; 308(4): 353-61.
[http://dx.doi.org/10.1001/jama.2012.6936] [PMID:  22820788] 
[54] 
Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med  1990; 112(9): 678-81.
[http://dx.doi.org/10.7326/0003-4819-112-9-678] [PMID:  2110430] 
[55] 
Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol  1992; 127(5): 513-8.
[http://dx.doi.org/10.1111/j.1365-2133.1992.tb14851.x] [PMID:  1467292] 
[56] 
Sarzi-Puttini P, D’Ingianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int  2005; 25(1): 15-22.
[http://dx.doi.org/10.1007/s00296-003-0384-2] [PMID:  14530867] 
[57] 
Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther  1997; 19(5): 913-23.
[http://dx.doi.org/10.1016/S0149-2918(97)80045-8] [PMID:  9385480] 
[58] 
Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet  2001; 358(9280): 455-60.
[http://dx.doi.org/10.1016/S0140-6736(01)05623-9] [PMID:  11513909] 
[59] 
van Jaarsveld CHM, Jahangier ZN, Jacobs JWG, et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford)  2000; 39(12): 1374-82.
[http://dx.doi.org/10.1093/rheumatology/39.12.1374] [PMID:  11136881] 
[60] 
Wasko MCM, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FGS. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: A randomised trial. Diabetologia  2015; 58(10): 2336-43.
[http://dx.doi.org/10.1007/s00125-015-3689-2] [PMID:  26197707] 
[61] 
Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: A multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol  2017; 69(4): 791-9.
[http://dx.doi.org/10.1002/art.40018] [PMID:  27992698] 
[62] 
Yoon CH, Lee HJ, Lee EY, et al. Effect of hydroxychloroquine treatment on dry eyes in subjects with primary sjögren’s syndrome: A double-blind randomized control study. J Korean Med Sci  2016; 31(7): 1127-35.
[http://dx.doi.org/10.3346/jkms.2016.31.7.1127] [PMID:  27366013] 
[63] 
Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: A retrospective cohort study. Arthritis Care Res (Hoboken)  2015; 67(4): 457-66.
[http://dx.doi.org/10.1002/acr.22483] [PMID:  25302481] 
[64] 
Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol  2019; 38(10): 2785-91.
[http://dx.doi.org/10.1007/s10067-019-04633-y] [PMID:  31175481] 
[65] 
Hsu C-Y, Lin Y-S, Su Y-J, et al. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: A database prospective cohort study. Rheumatology (Oxford)  2017; 56(12): 2212-21.
[http://dx.doi.org/10.1093/rheumatology/kex357] [PMID:  29029334] 
[66] 
Ju U-H, Liu F-C, Lin C-S, et al. Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study. Medicine (Baltimore)  2019; 98(14)e14984
[http://dx.doi.org/10.1097/MD.0000000000014984] [PMID:  30946325] 
[67] 
Alpay-Kanitez N, Pehlivan Ö, Omma A, et al. Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis. Medicine (Baltimore)  2020; 99(16)e19696
[http://dx.doi.org/10.1097/MD.0000000000019696] [PMID:  32311948] 
[68] 
Kumar A, Prakash AS. Effectiveness and safety of hydroxychloroquine compared to teneligliptin in uncontrolled T2DM patients as add-on Therapy. J ASEAN Fed Endocr Soc  2019; 34(1): 87-91.
[http://dx.doi.org/10.15605/jafes.034.01.13] [PMID:  33442141] 
[69] 
Sharma TS, Wasko MCM, Tang X, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc  2016; 5(1)e002867
[http://dx.doi.org/10.1161/JAHA.115.002867] [PMID:  26727968] 
[70] 
van Roeden SE, Bleeker-Rovers CP, de Regt MJA, et al. Treatment of chronic q fever: Clinical efficacy and toxicity of antibiotic regimens. Clin Infect Dis  2018; 66(5): 719-26.
[http://dx.doi.org/10.1093/cid/cix886] [PMID:  29040457] 
[71] 
Wu C-L, Chang C-C, Kor C-T, et al. Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis. Clin J Am Soc Nephrol  2018; 13(5): 702-9.
[http://dx.doi.org/10.2215/CJN.11781017] [PMID:  29661770] 
[72] 
Shipman WD, Vernice NA, Demetres M, Jorizzo JL. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. J Am Acad Dermatol  2020; 82(3): 709-22.
[http://dx.doi.org/10.1016/j.jaad.2019.07.027] [PMID:  31306730] 
[73] 
 Methotrexate 25 mg Tablets - Summary of Product Characteristics
(SmPC) - (emc) Available from: https://www.medicines.org.uk/emc/product/511/smpc#UNDESIRABLE_EFFECTS
Cite As
Current Reviews in Clinical and Experimental Pharmacology

A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine in a Randomized Controlled Trial and Observational Studies

Abstract
